Drug Search Results
More Filters [+]

Sevacizumab

Alternative Names: sevacizumab
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Humanized Anti-VEGF Monoclonal Antibody for Platinum-Resistant Recurrent Ovarian Cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03763123)

Mechanisms of Action: VEGF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Jiangsu Simcere
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sevacizumab

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20210585

P3

Not yet recruiting

Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer

None

Recent News Events